The Pap test reduces the incidence of cervical cancer and its precursors for women around the world but has limitations in sensitivity and accuracy.
Liquid-based cytology improves detection of dysplasia and cervical malignancy while producing fewer unsatisfactory or insufficient results. This supplement examines the science, development and clinical benefits of ThinPrep® - the first FDA-approved, liquid-based cytological testing method for women aged 30 and older.
Read this online supplement to learn more about the latest in developments in cervical cancer screening.
Download Supplement
A Legacy of Excellence: Reflecting on the Final Print Edition of Contemporary OB/GYN
April 25th 2025Marking the end of an era and the beginning of a new chapter, the final print edition of Contemporary OB/GYN celebrates over 50 years of evidence-based guidance and unwavering support for clinicians.
Read More